Skin probiotics to treat netherton syndrome
Ended Project Grant Awarded Last action
- Award ID
- R43AR082240
- Recipient
-
Resvita Bio Inc. UEI LE1LFZE6EMK5
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $499,870
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Netherton syndrome (NS) is a severe genetic disorder that affects the skin, hair, and immune system. NS is caused by mutations associated with the SPINK5 gene which encodes lekti (lympho-epithelial kazal-type inhibitor), a serine protease inhibitor. Normally, skin shedding is controlled by an extracellular balance between serine proteases and serine protease inhibitors, and mutations in lekti result in overactivity of serine proteases. There is not an FDA-approved therapy or consensus treatment of conditions, and symptoms are mostly managed through antibacterials, emollients and corticosteroids. An enzyme-replacement therapy of topically applied lekti could be an elegant solution, but the short half-life of lekti precludes this possibility. The skin microbiome is home to over 1011 bacteria, and provides an attractive target as a delivery vehicle through continuous delivery of lekti. Through synthetic biology, we will engineer a bacteria to colonize the skin surface and secrete bioactive lekti to restore balance to the skin shedding process. In this phase i sbir, we will establish the safety of our topical application in in vitro models and demonstrate bioactive secretion of lekti fragments. This will provide a strong foundation to transition to phase 2 where we will establish safety and efficacy in murine genetic models.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $249,935 | |
| Original award | $249,935 |
Quick answers
Who received award R43AR082240?
R43AR082240 was awarded to Resvita Bio Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 15, 2022.
How much is award R43AR082240 worth?
$499,870 has been obligated on R43AR082240.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award